JP7109160B2 - 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 - Google Patents

神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 Download PDF

Info

Publication number
JP7109160B2
JP7109160B2 JP2016573808A JP2016573808A JP7109160B2 JP 7109160 B2 JP7109160 B2 JP 7109160B2 JP 2016573808 A JP2016573808 A JP 2016573808A JP 2016573808 A JP2016573808 A JP 2016573808A JP 7109160 B2 JP7109160 B2 JP 7109160B2
Authority
JP
Japan
Prior art keywords
fxii
seq
injury
brain
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524675A5 (OSRAM
JP2017524675A (ja
Inventor
クリストフ・クラインシュニッツ
マルク・ノルテ
アンナ－レーナ・ジレン
クリスティアーネ・アルベルト－ヴァイセンベルガー
ザーラ・ホップ－クレーマー
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2017524675A publication Critical patent/JP2017524675A/ja
Publication of JP2017524675A5 publication Critical patent/JP2017524675A5/ja
Application granted granted Critical
Publication of JP7109160B2 publication Critical patent/JP7109160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016573808A 2014-06-18 2015-06-18 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 Active JP7109160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14172910 2014-06-18
EP14172910.3 2014-06-18
PCT/EP2015/063760 WO2015193457A1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder

Publications (3)

Publication Number Publication Date
JP2017524675A JP2017524675A (ja) 2017-08-31
JP2017524675A5 JP2017524675A5 (OSRAM) 2018-07-19
JP7109160B2 true JP7109160B2 (ja) 2022-07-29

Family

ID=50972542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573808A Active JP7109160B2 (ja) 2014-06-18 2015-06-18 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法

Country Status (12)

Country Link
US (2) US20170114119A1 (OSRAM)
EP (1) EP3157548B1 (OSRAM)
JP (1) JP7109160B2 (OSRAM)
KR (1) KR102513050B1 (OSRAM)
CN (1) CN106456778A (OSRAM)
AU (1) AU2015276089B2 (OSRAM)
BR (1) BR112016029624A2 (OSRAM)
CA (1) CA2950988C (OSRAM)
DK (1) DK3157548T3 (OSRAM)
ES (1) ES2886859T3 (OSRAM)
PL (1) PL3157548T3 (OSRAM)
WO (1) WO2015193457A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
CA3018375A1 (en) * 2016-03-30 2017-10-05 Carin Sjolund Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
KR20230136687A (ko) * 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법
BR112020011240A2 (pt) 2017-12-15 2020-11-24 Csl Limited uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica
WO2020113084A1 (en) * 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody
WO2022235551A2 (en) * 2021-05-03 2022-11-10 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP2014507390A (ja) 2010-12-17 2014-03-27 アントフロゲネシス コーポレーション 胎盤幹細胞を用いる脊髄損傷及び外傷性脳損傷の治療

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
AU2005318464B2 (en) * 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
JP2010518039A (ja) 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
RS66465B1 (sr) 2011-07-22 2025-02-28 Csl Behring Gmbh Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe
ES2714999T3 (es) 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
PL3013366T3 (pl) 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
US9587903B2 (en) 2014-02-24 2017-03-07 Brian E. Sullivan Pneumatic launcher system and method
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
KR20230136687A (ko) 2016-04-06 2023-09-26 시에스엘 리미티드 죽상동맥경화증의 치료 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507390A (ja) 2010-12-17 2014-03-27 アントフロゲネシス コーポレーション 胎盤幹細胞を用いる脊髄損傷及び外傷性脳損傷の治療
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ， １９８１， Ｖｏｌ．４１， ｐｐ．２１０３－２１０８，検索日：２０２２年１月２８日、＜ｈｔｔｐｓ：／／ｃａｎｃｅｒｒｅｓ．ａａｃｒｊｏｕｒｎａｌｓ．ｏｒｇ／ｃｏｎｔｅｎｔ／ｃａｎｒｅｓ／４１／６／２１０３．ｆｕｌｌ．ｐｄｆ＞
Ｃｉｒｃｕｌａｔｉｏｎ，２０１０年，Ｖｏｌ．１２１，Ｎｏ．１３，ｐ１５１０－１５１７
ＭＳＤ マニュアル プロフェッショナル版 外傷性脳損傷（ＴＢＩ）、最終査読／改訂年月 ２０１７年 １１月、検索日：２０２１年６月１７日、＜ＵＲＬ： ｈｔｔｐｓ：／／ｗｗｗ．ｍｓｄｍａｎｕａｌｓ．ｃｏｍ／ｊａ－ｊｐ／％Ｅ３％８３％９７％Ｅ３％８３％ＡＤ％Ｅ３％８３％９５％Ｅ３％８２％Ａ７％Ｅ３％８３％８３％Ｅ３％８２％Ｂ７％Ｅ３％８３％Ａ７％Ｅ３％８３％８Ａ％Ｅ３％８３％ＡＢ／２２－％Ｅ５％Ａ４％９６％Ｅ５％８２％Ｂ７％Ｅ３％８１％Ａ８％Ｅ４％Ｂ８％ＡＤ％Ｅ６％ＡＦ％９２／％Ｅ５％Ａ４％９６％Ｅ５％８２％Ｂ７％Ｅ６％８０％Ａ７％Ｅ８％８４％Ｂ３％Ｅ６％９０％８Ｄ％Ｅ５％８２％Ｂ７－％ＥＦ％ＢＣ％８８ｔｂｉ％ＥＦ％ＢＣ％８９／％Ｅ５％Ａ４％９６％Ｅ５％８２％Ｂ７％Ｅ６％８０％Ａ７％Ｅ８％８４％Ｂ３％Ｅ６％９０％８Ｄ％Ｅ５％８２％Ｂ７％ＥＦ％ＢＣ％８８ｔｂｉ％ＥＦ％ＢＣ％８９＞
ＮＣＢＩ Ｃ１Ｓ ｃｏｍｐｌｅｍｅｎｔ Ｃ１ｓ［Ｈｏｍｏ ｓａｐｉｅｎｓ（ｈｕｍａｎ）］、検索日：２０２２年１月２８日、＜ｈｔｔｐｓ：／／ｗｗｗ．ｎｃｂｉ．ｎｌｍ．ｎｉｈ．ｇｏｖ／ｇｅｎｅ／７１６＞
Ｐｒｏｇｒｅｓｓ ｉｎ Ｎｅｕｒｏｂｉｏｌｏｇｙ，２０１３年，Ｖｏｌ．１０１－１０２，ｐ６５－８２
血栓止血誌 ２０１４， Ｖｏｌ．２５， Ｎｏ．１， ｐｐ．２３－３２、検索日：２０２２年１月２８日、＜ｈｔｔｐｓ：／／ｗｗｗ．ｊｓｔａｇｅ．ｊｓｔ．ｇｏ．ｊｐ／ａｒｔｉｃｌｅ／ｊｊｓｔｈ／２５／１／２５＿２３／＿ｐｄｆ／－ｃｈａｒ／ｊａ＞
血栓止血誌， ２０１４， Ｖｏｌ．２５， Ｎｏ．３， ｐｐ．４１１－４２２，検索日：２０２１年６月１７日、＜ＵＲＬ： ｈｔｔｐｓ：／／ｗｗｗ．ｊｓｔｈ．ｏｒｇ／ｐｕｂｌｉｃａｔｉｏｎｓ／ｐｄｆ／ｊｓｔａｇｅ／％Ｅ７％９９％ＢＡ％Ｅ７％８Ｆ％ＢＥ％Ｅ６％Ａ９％９Ｆ％Ｅ６％Ａ７％８Ｂ２５－３．ｐｄｆ＞

Also Published As

Publication number Publication date
AU2015276089B2 (en) 2021-03-18
CN106456778A (zh) 2017-02-22
US12065481B2 (en) 2024-08-20
AU2015276089A1 (en) 2017-02-02
BR112016029624A2 (pt) 2017-10-24
WO2015193457A1 (en) 2015-12-23
US20200131248A1 (en) 2020-04-30
KR20170016503A (ko) 2017-02-13
CA2950988A1 (en) 2015-12-23
CA2950988C (en) 2024-02-06
PL3157548T3 (pl) 2022-01-17
US20170114119A1 (en) 2017-04-27
ES2886859T3 (es) 2021-12-21
KR102513050B1 (ko) 2023-03-29
DK3157548T3 (da) 2021-09-06
EP3157548A1 (en) 2017-04-26
EP3157548B1 (en) 2021-08-04
JP2017524675A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
US12065481B2 (en) Therapy using a factor XII inhibitor in a neurotraumatic disorder
JP6243854B2 (ja) 神経炎症性障害の処置のための第ｘｉｉ因子阻害剤
JP7768560B2 (ja) 好中球エラスターゼ活性のポリペプチド阻害剤およびその使用
HK1232804B (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200722

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200918

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200923

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201023

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201027

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210420

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220301

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220517

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220614

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220712

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220719

R150 Certificate of patent or registration of utility model

Ref document number: 7109160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250